Certara to Open New Office in China
The new office will provide the company with opportunities to collaborate more efficiently with customers in the Chinese biopharmaceutical industry.
Certara, a US-based biosimulation company, is opening a new office in Shanghai, China’s Pudong District, a hub for biopharmaceutical research and development.
The new office will provide the company with opportunities to collaborate more efficiently with customers in the Chinese biopharmaceutical industry, a Nov. 9, 2020 company press release said.
“We recognize the tremendous growth of China’s biopharmaceutical industry and are thrilled to have a direct presence in China so that we can fully support our rapidly growing Chinese customer base,” said William F. Feehery, PhD, CEO of Certara, in the press release. “Certara’s extensive experience in biosimulation and our partnerships with top global biopharmaceutical companies will help foster innovation in China, accelerate time-to-market for our customers, and most importantly, improve patient outcomes.”
Source: Certara
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
